Endonovo Therapeutics Inc. (ENDV) 5.3100 $ENDV
Endonovo Therapeutics to Develop Next Generation, Off-The-Shelf, Cell Free Regenerative Products
Marketwire - Wed Jun 11, 8:03AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a biotechnology company developing innovative regenerative therapies, announced today that it has created technologies to pursue the development and manufacturing of next generation regenerative products that no longer require the administration of stem cells. Endonovo's "Cell Free" products will harness the biological molecules secreted by cells to create truly "off-the-shelf" therapeutics that can be delivered to patients in a much timelier manner than is possible with autologous and allogeneic stem cell therapies.
Endeavour Comments on Stock Price and Updates Q2 2014 Guidance
PR Newswire - Tue Jun 10, 8:17AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that it has received numerous calls from analysts and investors making inquiries regarding recent market activity in the Company's stock. Management of the Company is unaware of any reason why recent trading of the stock has resulted in a significant decrease in its price over the last few days.
Stockholders Elect ALL Endeavour Director Nominees at Annual Meeting
PR Newswire - Thu May 22, 3:15PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that, based on the preliminary vote count of its proxy solicitor, Morrow & Co., Endeavour's stockholders have elected all of the Board of Director's director nominees - John B. Connally III, James H. Browning and William D. Lancaster - at the Company's 2014 Annual Meeting of Stockholders.
Endeavour Announces Both Wells on Production at Rochelle Field
PR Newswire - Wed May 21, 8:00AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) ("Endeavour" or the "Company" today announced that the West Rochelle W1 well has been returned to production. Both West and East Rochelle wells are now flowing together and Rochelle production will be optimized between the two wells in the coming days. The Company may update production guidance for the second quarter, once stabilized production rates have been achieved.
Leading Proxy Advisory Firm Egan-Jones Recommends That Endeavour Stockholders Elect All of Endeavour's Director Nominees
PR Newswire - Mon May 19, 4:28PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that Egan-Jones Proxy Services ("Egan-Jones", a leading proxy advisory firm, has recommended that Endeavour stockholders vote "FOR" all three of Endeavour's highly-qualified and experienced director nominees on the WHITE proxy card and "FOR" all proposals up for consideration at the Company's 2014 Annual Meeting of Stockholders to be held on May 22, 2014.
Leading Proxy Advisory Firm ISS Recommends That Endeavour Stockholders Elect All of Endeavour's Director Nominees
PR Newswire - Fri May 16, 8:07AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that Institutional Shareholder Services ("ISS", the nation's leading proxy advisory firm, has recommended that Endeavour stockholders vote "FOR" all three of Endeavour's highly-qualified and experienced director nominees on the WHITE proxy card at the Company's 2014 Annual Meeting of Stockholders to be held on May 22, 2014.
Endonovo Therapeutics Affects 1-for-100 Reverse Stock Split
Marketwire - Thu May 15, 8:03AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", formerly Hanover Portfolio Acquisitions, Inc. (OTCQB: HVPA), a biotechnology company developing bioelectronic and cell based therapies, today announced that it has affected a 1-for-100 reverse stock split and disclosed a plan to recapitalize the Company's balance sheet in order to make the Company's common stock more attractive to a broader range of institutional investors and to begin meeting the minimum initial listing requirements of the NASDAQ Capital Market.
Endeavour Sends Letter to Stockholders
PR Newswire - Wed May 14, 8:29AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that it is mailing a letter to stockholders in connection with the 2014 Annual Meeting of Stockholders scheduled for May 22, 2014.
Endeavour Announces 2014 First Quarter Financial and Operational Results
PR Newswire - Wed May 07, 1:00AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today reported first quarter 2014 net loss, as adjusted of $27.3 million compared to a net loss, as adjusted of $12.1 million for the same period in 2013. On a GAAP basis, net loss for the first quarter was $44.9 million as compared to net loss of $14.0 million for the same quarter in 2013.
Endonovo Therapeutics Changes Ticker Symbol to ENDV
Marketwire - Mon May 05, 8:03AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company", formerly Hanover Portfolio Acquisitions, Inc. (OTCQB: HVPA), a biotechnology company developing bioelectronic and cell based therapies, announced today that the Company is now trading under the new symbol ENDV, effective May 5, 2014. The change is in accordance with the exchange's recognition of the Company's name change outlined in the 8K filed January 24, 2014. All stock trading, filings and market related information will be traded under the new ticker symbol ENDV.
Endeavour to Present at the Howard Weil Energy Conference
PR Newswire - Tue Mar 25, 3:15PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that it will present at the Howard Weil's 42nd Annual Energy Conference. William L. Transier, chairman, chief executive officer and president, is scheduled to speak on the company's business strategies and operational plans on Thursday, March 27, 2014 at 11:00 am Central time.
Endeavour Announces New Board Member
PR Newswire - Wed Mar 19, 3:29PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that James H. Browning has been appointed to a serve as a Director on the company's Board of Directors. He will serve as an independent director and be appointed to both the Technology & Reserves Committee and Audit Committee, where he qualifies as an "audit committee financial expert."
Endeavour Announces 2013 Fourth Quarter and Year-End Financial and Operational Results
PR Newswire - Wed Mar 05, 1:00AM CST
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today reported fourth quarter 2013 net loss, as adjusted of $24.7 million compared to a net loss, as adjusted of $7.7 million for the same period in 2012. On a GAAP basis, net loss for the fourth quarter was $27.7 million as compared to net loss of $6.5 million for the same quarter in 2012.
Endonovo Therapeutics to Develop Next Generation, Off-The-Shelf, Cell Free Regenerative Products
Marketwire - Wed Jun 11, 8:03AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, a biotechnology company developing innovative regenerative therapies, announced today that it has created technologies to pursue the development and manufacturing of next generation regenerative products that no longer require the administration of stem cells. Endonovo's "Cell Free" products will harness the biological molecules secreted by cells to create truly "off-the-shelf" therapeutics that can be delivered to patients in a much timelier manner than is possible with autologous and allogeneic stem cell therapies. Endeavour Comments on Stock Price and Updates Q2 2014 Guidance
PR Newswire - Tue Jun 10, 8:17AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that it has received numerous calls from analysts and investors making inquiries regarding recent market activity in the Company's stock. Management of the Company is unaware of any reason why recent trading of the stock has resulted in a significant decrease in its price over the last few days.
Stockholders Elect ALL Endeavour Director Nominees at Annual Meeting
PR Newswire - Thu May 22, 3:15PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that, based on the preliminary vote count of its proxy solicitor, Morrow & Co., Endeavour's stockholders have elected all of the Board of Director's director nominees - John B. Connally III, James H. Browning and William D. Lancaster - at the Company's 2014 Annual Meeting of Stockholders.
Endeavour Announces Both Wells on Production at Rochelle Field
PR Newswire - Wed May 21, 8:00AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) ("Endeavour" or the "Company"
today announced that the West Rochelle W1 well has been returned to production. Both West and East Rochelle wells are now flowing together and Rochelle production will be optimized between the two wells in the coming days. The Company may update production guidance for the second quarter, once stabilized production rates have been achieved. Leading Proxy Advisory Firm Egan-Jones Recommends That Endeavour Stockholders Elect All of Endeavour's Director Nominees
PR Newswire - Mon May 19, 4:28PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that Egan-Jones Proxy Services ("Egan-Jones"
, a leading proxy advisory firm, has recommended that Endeavour stockholders vote "FOR" all three of Endeavour's highly-qualified and experienced director nominees on the WHITE proxy card and "FOR" all proposals up for consideration at the Company's 2014 Annual Meeting of Stockholders to be held on May 22, 2014. Leading Proxy Advisory Firm ISS Recommends That Endeavour Stockholders Elect All of Endeavour's Director Nominees
PR Newswire - Fri May 16, 8:07AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that Institutional Shareholder Services ("ISS"
, the nation's leading proxy advisory firm, has recommended that Endeavour stockholders vote "FOR" all three of Endeavour's highly-qualified and experienced director nominees on the WHITE proxy card at the Company's 2014 Annual Meeting of Stockholders to be held on May 22, 2014. Endonovo Therapeutics Affects 1-for-100 Reverse Stock Split
Marketwire - Thu May 15, 8:03AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, formerly Hanover Portfolio Acquisitions, Inc. (OTCQB: HVPA), a biotechnology company developing bioelectronic and cell based therapies, today announced that it has affected a 1-for-100 reverse stock split and disclosed a plan to recapitalize the Company's balance sheet in order to make the Company's common stock more attractive to a broader range of institutional investors and to begin meeting the minimum initial listing requirements of the NASDAQ Capital Market. Endeavour Sends Letter to Stockholders
PR Newswire - Wed May 14, 8:29AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that it is mailing a letter to stockholders in connection with the 2014 Annual Meeting of Stockholders scheduled for May 22, 2014.
Endeavour Announces 2014 First Quarter Financial and Operational Results
PR Newswire - Wed May 07, 1:00AM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today reported first quarter 2014 net loss, as adjusted of $27.3 million compared to a net loss, as adjusted of $12.1 million for the same period in 2013. On a GAAP basis, net loss for the first quarter was $44.9 million as compared to net loss of $14.0 million for the same quarter in 2013.
Endonovo Therapeutics Changes Ticker Symbol to ENDV
Marketwire - Mon May 05, 8:03AM CDT
Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"
, formerly Hanover Portfolio Acquisitions, Inc. (OTCQB: HVPA), a biotechnology company developing bioelectronic and cell based therapies, announced today that the Company is now trading under the new symbol ENDV, effective May 5, 2014. The change is in accordance with the exchange's recognition of the Company's name change outlined in the 8K filed January 24, 2014. All stock trading, filings and market related information will be traded under the new ticker symbol ENDV. Endeavour to Present at the Howard Weil Energy Conference
PR Newswire - Tue Mar 25, 3:15PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that it will present at the Howard Weil's 42nd Annual Energy Conference. William L. Transier, chairman, chief executive officer and president, is scheduled to speak on the company's business strategies and operational plans on Thursday, March 27, 2014 at 11:00 am Central time.
Endeavour Announces New Board Member
PR Newswire - Wed Mar 19, 3:29PM CDT
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today announced that James H. Browning has been appointed to a serve as a Director on the company's Board of Directors. He will serve as an independent director and be appointed to both the Technology & Reserves Committee and Audit Committee, where he qualifies as an "audit committee financial expert."
Endeavour Announces 2013 Fourth Quarter and Year-End Financial and Operational Results
PR Newswire - Wed Mar 05, 1:00AM CST
Endeavour International Corporation (NYSE: END) (LSE: ENDV) today reported fourth quarter 2013 net loss, as adjusted of $24.7 million compared to a net loss, as adjusted of $7.7 million for the same period in 2012. On a GAAP basis, net loss for the fourth quarter was $27.7 million as compared to net loss of $6.5 million for the same quarter in 2012.
